All In Biotech

Drug Trial Radar · NCT01725802

A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients

A Phase I/IIa, Single Dose, Single-centre, Randomized, Crossover, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients

Last checked: Nov 19, 2026Latest source record: May 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Dec 16, 2012

Primary completion

Feb 26, 2013

Study completion Feb 26, 2013

Sponsor

Lead sponsor
NeuroDerm Ltd.Industry
Sponsor type
Industry
First posted
Nov 14, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this Phase I/IIa study, the effect of continuous subcutaneous administration of LD/CD solution (ND0612) on the safety and PK profile of LD will be examined.

Conditions

  • Parkinson's Disease

Interventions

  • Levodopa/carbidopa solution for SC administrationDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and frequency of adverse eventsTime frame: up to 8 weeks
  2. Withdrawal rateTime frame: 2 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hadassah Medical Center

    Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.